At the European Society of Cardiology Congress 2016 in Rome, Italy, Array Biopharma (ARRY) presented good results from a Phase 2 study of its drug ARRY-797 - an oral, selective p38 mitogen-activated protein kinase inhibitor for patients with a rare degenerative cardiovascular disease. The disease, is known as lamin A/C-related dilated cardiomyopathy (LMNA-related DCM) and is caused by mutations in the LMNA gene and is known to have a poor prognosis.

In other words, Array’s drug ARRY-797 faired well in improving patients’ deadly disease caused by a mutated gene.

The drug demonstrated . . .